Unicycive Therapeutics (UNCY) Q1 2025 earnings summary

Executive summary

• Focused on developing therapies for kidney disease, with two main programs: Oxylanthanum Carbonate (OLC) for hyperphosphatemia and UNI-494 for acute kidney injury; OLC NDA is under FDA review with a PDUFA date of June 28, 2025, and commercial launch preparations are underway for late 2025.

• New patient survey and outcomes data highlight adherence challenges and strong preference for OLC due to reduced pill burden; presentations at major nephrology conferences increased awareness of OLC's potential benefits.

• Net income of $0.6 million for Q1 2025, compared to a net loss of $21.0 million in Q1 2024, driven by a favorable change in warrant liability valuation.

• Accumulated deficit stands at $100.7 million as of March 31, 2025.

• Company expects to continue incurring losses and will require additional capital to fund operations.

Financial highlights

• Total revenue remains negligible; primary income is from financing activities and changes in warrant liability.

• Operating expenses decreased 13% year-over-year to $8.0 million in Q1 2025; R&D expenses fell 68% to $2.2 million, while G&A expenses rose 143% to $5.8 million, mainly due to commercial launch preparation.

• Net income attributable to common stockholders was $0.5 million for Q1 2025, compared to a net loss of $21.2 million in Q1 2024, primarily due to a decrease in warrant liability fair value.

• Net cash used in operating activities was $8.9 million for Q1 2025.

• Cash and cash equivalents were $19.8 million at quarter-end, down from $26.1 million at December 31, 2024.

Outlook and guidance

• Management expects continued losses and negative cash flows from operations; current cash is not sufficient to fund planned expenditures through Q1 2026, raising substantial doubt about going concern status.

• Ongoing commercial planning for OLC in anticipation of FDA approval and launch in late 2025; continued focus on manufacturing commercial supplies, reflected in increased prepaid expenses and current assets.

• Additional capital will be needed for clinical trials, product development, and commercialization.